REGENXBIO, a biotech focused on gene therapies, has raised $70.5 million in Series D funding co-led by new investor Vivo Capital and existing investors Venrock and Brookside Capital. The company previously raised funds in January, bringing in $30 million at a valuation of $90 million; altogether, REGENXBIO has raised more than $110 million in equity rounds.
The fresh capital will be used to advance REGENXBIO's lead programs through clinical development and add to its pipeline of therapies. As part of the financing, Edgar Engleman of Vivo Capital will join the company's Board. Chardan Capital Markets served as sole placement agent for the transaction, while Gunderson Dettmer served as legal advisor to REGENXBIO.